查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024620

霍亂疫苗市場報告：按疫苗類型、產品類型、最終用戶和地區分類（2026-2034 年）

Cholera Vaccines Market Report by Vaccine Type, Product, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年全球霍亂疫苗市場規模達650萬美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到1,430萬美元，2026年至2034年的複合年成長率為8.85%。該市場正經歷穩定成長，主要受霍亂病例增加（尤其是在衛生條件差的地區）、全球各國政府加大支持和資金投入以及疫苗技術的不斷進步等因素的推動。

霍亂疫苗市場趨勢

提高大眾意識和預防霍亂

根據美國國家醫學圖書館的報導，全球霍亂感染人數估計為290萬（130萬至400萬），死亡人數為9.5萬（2.1萬至14.3萬），其中60%的病例報告於撒哈拉以南非洲，29%報告於東南亞。隨著社會各界認知到霍亂疫情的致命性，採取包括疫苗接種在內的適當預防措施的步伐正在加快。因此，霍亂疫苗在預防中的廣泛應用和免疫接種的推廣正在推動霍亂疫苗行業的成長。公共衛生宣傳活動、教育和主流媒體提高公眾意識，有助於彌合知識鴻溝，這對於防止霍亂的持續傳播至關重要。此外，個人和社區對疫苗接種日益成長的興趣促使各國政府、衛生機構和國際組織增加對疫苗宣傳活動的資源投入，從而促進市場成長。

疫苗技術的進步

疫苗技術的持續進步也是市場擴張的關鍵。因此，新型口服霍亂疫苗（OCV）提供了更有效、更經濟的預防措施。霍亂疫苗市場分析表明，新型抗病毒藥物的改進使第二代疫苗效力更強，提供更持久的保護，更容易接種。它們只需單劑接種，即使在惡劣條件下也能長期儲存，這些特點增強了它們的吸引力。此外，持續的研發工作預計在未來推出更多新型疫苗，不僅有助於市場擴張，也有助於最終根除霍亂。

政府支持措施和資金

根據霍亂疫苗市場概覽，政府加強支持以及國際組織的資金投入是推動市場成長的主要因素。此外，霍亂流行地區的各國政府正在實施衛生措施和免疫接種計劃，以控制霍亂的傳播。世界衛生組織也支持旨在維持高疫苗接種率的大規模宣傳活動，尤其是在疫情持續爆發的地區。此外，疫苗的核准流程和快速部署對於控制霍亂相關突發事件至關重要，並顯著促進了霍亂疫苗市場的成長。同時，全球對加強公共衛生基礎設施和醫療衛生系統的重視也持續推高了全球對霍亂疫苗的需求。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球霍亂疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依疫苗類型分類

  • 含重組B次單元的霍亂弧菌O1全細胞疫苗
  • 去活化口服疫苗（O1 和 O139）

第7章 市場區隔：依產品分類

  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol 和 Euvichol-Plus
  • 其他

第8章 市場區隔：依最終用戶分類

  • 醫院和診所
  • 研究和學術實驗室
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Astellas Pharma Inc.
    • Celldex Therapeutics Inc.（Avant Immunotherapeutics Inc.）
    • Emergent BioSolutions Inc.
    • Eubiologics Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc
    • Pfizer Inc.
    • PharmaChoice Canada Inc
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited.
    • Valneva SE
Product Code: SR112026A4973

The global cholera vaccines market size reached USD 6.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 14.3 Million by 2034, exhibiting a growth rate (CAGR) of 8.85% during 2026-2034. The market is experiencing steady growth driven by rising cholera cases, particularly in regions with poor sanitation and hygiene, the accelerating supportive government policies and funding across the globe, and continuous technological advancements in vaccine technology.

CHOLERA VACCINES MARKET ANALYSIS:

  • Major Market Drivers: The growing incidents of cholera outbreaks in areas with inadequate sanitation and lack of access to clean water drive the market. It is also supported due to efforts taken by the government and substantial investments in vaccine campaigns by global health organizations.
  • Key Market Trends: Some of the cholera vaccines market trends include the newer group of cholera vaccines. The new products offer better results and are longer-lasting. A tool of this capacity is a game changer, particularly in resource-poor settings. Moreover, the shift of single and long-term vaccines makes them cheaper and more convenient.
  • Geographical Trends: High demand for cholera vaccines is seen in endemic areas of Africa, Asia, and parts of the Americas, where the burden of disease is most severe. International organizations, together with governments in the class, have made vaccination campaigns a priority to prevent and stem cholera outbreaks.
  • Competitive Landscape: The cholera vaccine market is a dynamic industry with key players such as Valneva SE, Sanofi, and Eubiologics Co., Ltd leading the charge. These companies invest heavily in research and development, constantly encouraging the envelope with new techniques.
  • Challenges and Opportunities: One of the main challenges is the complex system of vaccination in remote and underdeveloped areas, which affects vaccination coverage. However, this acts as one of the cholera vaccines market recent opportunities and is supported by funding for international health organizations to attend so, has advanced vaccine technology and improved its development.

CHOLERA VACCINES MARKET TRENDS:

Increasing awareness and cholera prevention

According to an article in the National Library of Medicine, the disease is responsible for an estimated 2.9 million (1.3-4 million) global prevalence and 95,000 (21,000-143,000) deaths, with 60% and 29% of cases reported in Sub-Saharan Africa and South-East Asia, respectively. As communities learn how deadly cholera episodes can be, the shift for proper prevention including vaccines is accelerating. The growing use of vaccines in cholera prevention and the promotion of mnemonic vaccination is thus expanding the cholera vaccines industry. The increasing awareness brought about by public health campaigns, education, and popular media helps close the knowledge gap, which is crucial in preventing the continued spread of cholera. In addition, the increasing interest in vaccination on a personal level and a grassroots community level is encouraging government, healthcare organizations, and international agencies to drive resource allocation to vaccination campaigns, thereby pushing market growth.

Advancements in vaccine technology

The continuous improvements in vaccine technology are also key to the expansion of the market. Along with this, newer oral cholera vaccines (OCVs) are offering more efficacious and cost-effective immunization tools. According to the cholera vaccines market analysis, improvements in the new antiviral drugs are aiding the second-generation vaccines to be even more potent, achieve longer-term protection, and be more convenient to deliver. Their single-dose regimens and capability to maintain in difficult storage conditions for long periods are improving their attractiveness. In addition, continuous research and development initiatives are launching new vaccines in the future, which is, therefore, aiding in the market expansion as well as the successful eradication of cholera.

Supportive government policies and funding

According to the cholera vaccines market overview, supportive government policies and rising funding from international organizations are one of the major factors driving the market. Along with this, the national authorities across cholera-endemic areas are applying health policies and vaccination plans to control the spread of cholera. In addition, international health organizations support massive campaigns. Its objectives are to maintain high vaccination coverage, especially in areas with endemic circulation. Moreover, the process of licensing and the swift deployment of vaccines are crucial for controlling cholera-related emergencies, significantly fueling cholera vaccines market growth. In addition, the global focus on strengthening public health infrastructure and preventive healthcare systems is providing for a sustained demand for cholera vaccines across the world.

CHOLERA VACCINES MARKET SEGMENTATION:

Breakup by Vaccine Type:

  • Whole Cell V. Cholerae O1 with Recombinant B-Subunit
  • Killed Oral O1 and O139

Whole cell V. cholerae O1 with recombinant B-subunit dominates the market

The whole cell V. cholerae O1 with recombinant B-subunit holds the largest cholera vaccines market share. It consists of whole cells of the Vibrio cholerae O1 strain, inactivated by formalin and combined with the recombinant B subunit of cholera toxin. The efficacy, oral vaccine preparations, and dual systemic and mucosal immunization efficacy of this formulation are responsible for dominance. Furthermore, the long-term shelf life and lowered cold chain requirements of this vaccine render it an appealing vaccine regimen for deployment in endemic as well as limited resource settings. As it is highly efficacious, and efficient, and can prevent disease outbreaks at source, governments and health organizations are emphasizing its use in mass vaccination campaigns, bolstering the cholera vaccines demand.

Breakup by Product:

  • Dukoral
  • Shanchol
  • Vaxchora
  • Euvichol and Euvichol-Plus
  • Others

Dukoral dominates the market

The cholera vaccines segment is further categorized into Dukoral, an oral cholera vaccine (OCV), which has the highest acceptance and efficacy. Also, Dukoral (developed by Valneva SE) provides dual protection against both cholera and traveler's diarrhea due to enterotoxigenic Escherichia coli (ETEC), which is especially important for those traveling to endemic areas. Therefore, it has a large share of cholera vaccines market revenue. The combination vaccine leads to improved immunization due to broad immunity induced by killed whole cells of Vibrio cholerae O1 combined with a recombinant cholera toxin B subunit. Worldwide approval of the vaccine, including from major regulatory authorities such as the World Health Organization (WHO) and the European Medicines Agency (EMA), further supports its global availability. Furthermore, supported by effective marketing strategies and well-established distribution networks are intensifying the market. It is licensed in endemic as well as non-endemic areas and is also leading the global cholera vaccine market according to the cholera vaccines market forecast.

Breakup by End User:

  • Hospitals and Clinics
  • Research and Academic Laboratories
  • Others

Hospitals and clinics dominate the market

Cholera vaccines fall into the category of vaccines and are purchased by common consumers, agencies, and corporations as well as hospitals and clinics, which are the largest end-user segment in the market. In addition, continuous advancements in vaccine technology are one of the cholera vaccines market recent developments. Along with this, hospitals and clinics would have the capacity in terms of cold storage and well-trained medical staff for vaccine storage and administration. Their existing social connections and confidence also help to accomplish a higher uptake of vaccination, especially in the more cholera-prone regions. In addition, these institutions are frequently partners in government and international health organizations' efforts to control cholera epidemics. Hospitals and clinics are responsible for making vaccines widely available and getting individuals vaccinated by providing routine immunization services and preparing to respond quickly to an epidemic. Therefore, they are certain to remain the most prevailing end users in the cholera vaccine market, the cholera vaccines market report states.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the cholera vaccines industry include

  • Astellas Pharma Inc.
  • Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
  • Emergent BioSolutions Inc.
  • Eubiologics Co. Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Pfizer Inc.
  • PharmaChoice Canada Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE

Major players in the market continue to develop and expand their market presence associated with licensing agreements, product launches, and novel distribution networks. Cholera vaccines companies are targeting its advanced oral cholera vaccine to expand its availability in endemic settings. They also are highlighting building up their supply chain and expanding their product offering to fill global health gaps. In addition, their capabilities to develop affordable and effective vaccines are crucial in targeting underserved populations, thereby addressing significant health disparities in regions most affected by cholera. Moreover, they are collaborating with government and non-governmental partners to enhance vaccination programs for comprehensive and coordinated cholera prevention and control efforts which is creating a positive cholera vaccines market outlook.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cholera Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Vaccine Type

  • 6.1 Whole Cell V. Cholerae O1 with Recombinant B-Subunit
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Killed Oral O1 and O139
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Dukoral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Shanchol
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Vaxchora
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Euvichol and Euvichol-Plus
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research and Academic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Astellas Pharma Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Emergent BioSolutions Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eubiologics Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 PharmaChoice Canada Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sanofi S.A.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Takeda Pharmaceutical Company Limited.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Valneva SE
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cholera Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Cholera Vaccines Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Cholera Vaccines Market: Breakup by Vaccine Type (in %), 2025
  • Figure 5: Global: Cholera Vaccines Market: Breakup by Product (in %), 2025
  • Figure 6: Global: Cholera Vaccines Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Cholera Vaccines Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Cholera Vaccines (Whole Cell V. Cholerae O1 with Recombinant B-Subunit) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Cholera Vaccines (Killed Oral O1 and O139) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Cholera Vaccines (Killed Oral O1 and O139) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Cholera Vaccines (Dukoral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Cholera Vaccines (Dukoral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Cholera Vaccines (Shanchol) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Cholera Vaccines (Shanchol) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Cholera Vaccines (Vaxchora) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Cholera Vaccines (Vaxchora) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Cholera Vaccines (Euvichol and Euvichol-Plus) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Cholera Vaccines (Other Product) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Cholera Vaccines (Other Product) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Cholera Vaccines (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Cholera Vaccines (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Cholera Vaccines (Research and Academic Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Cholera Vaccines (Research and Academic Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Cholera Vaccines (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Cholera Vaccines (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Cholera Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Cholera Vaccines Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Cholera Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Cholera Vaccines Industry: SWOT Analysis
  • Figure 78: Global: Cholera Vaccines Industry: Value Chain Analysis
  • Figure 79: Global: Cholera Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cholera Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cholera Vaccines Market Forecast: Breakup by Vaccine Type (in Million USD), 2026-2034
  • Table 3: Global: Cholera Vaccines Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 4: Global: Cholera Vaccines Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Cholera Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Cholera Vaccines Market: Competitive Structure
  • Table 7: Global: Cholera Vaccines Market: Key Players